Further Data Against the Use of Cyproterone Acetate in Gender-Affirming Hormone Therapy Regimens

1

A randomized trial found no significant difference in breast development between cyproterone acetate and spironolactone in transgender individuals.
2

Cyproterone acetate is linked to potential adverse effects, including dyslipidemia and meningioma, raising concerns about its use in hormone therapy.
3

Spironolactone is generally well tolerated with fewer serious side effects, making it a safer alternative for adjunct antiandrogen therapy.
4

The study suggests that the choice of antiandrogen should be individualized, emphasizing shared decision-making in treatment options.
5

Overall, evidence indicates that cyproterone acetate may not offer additional benefits compared to spironolactone in feminizing hormone therapy.

1